A First-in-Human Trial Offers Hope for CAR-T in Solid Tumors
CAR-T has seen most of its success in blood cancers, but a first-in-human trial of CAR-T in solid tumors is under way.
CAR-T Therapy
PI3K Inhibitors Increased T-Cell Expansion Ahead of CAR-T Cell Therapy
Concomitant use of inhibitors allowed for the manufacture of more potent T cells.
Immunoglobulin Replacement May Benefit Some Patients Receiving CAR-T Therapy
CAR-T therapy can sometimes lead to immune system dysfunction, subsequent hypogammaglobulinemia, and the need for antibody replacement therapy.
BELINDA Trial Tests Earlier Use of Tisa-Cel in Aggressive B-Cell Non-Hodgkin Lymphoma
Bumping CAR-T cell therapy earlier in the treatment protocol could reduce toxicity and improve survival for patients with relapsed or refractory disease.
Armed “Bionic” T Cells Show Preclinical Cytotoxic Activity — No CAR Required
A “bionic” T cell that is armed with a bispecific antibody but lacks a chimeric antigen receptor showed cytotoxic activity in cancer cell lines.
Liso-Cel Shows Durable Activity in Diffuse Large B-Cell Lymphoma
Lisocabtagene maraleucel appeared to have durable clinical activity in patients with relapsed/refractory diffuse large B-cell lymphoma.
Better Short-Term QoL, Fewer Symptoms With CAR-T vs SCT in Hematologic Malignancies
While PRO-CTCAEs capture patient reports of particular symptomatic AEs, the “toxicity over time” approach provides a longitudinal assessment of these AEs.
CAR-T Therapy May Be Associated With Decreased Utilization of Health Care Resources in Older, “Real-World” Patients With NHL
In this study, claims data from CMS were used to estimate health care utilization of patients with DLCBL before and after CAR-T therapy.
More Evidence Supporting the Benefit of Anti-BCMA CAR-T in R/R Multiple Myeloma: The CARTITUDE Study
JNJ-4528 is a CAR-T therapy in which 2 antibodies against the B-cell maturation antigen BCMA are expressed on T cells.
A Subset of Patients With B-Cell Malignancies May Benefit From a Second CAR-T Infusion
Some patients with progressive disease or a partial response to a first infusion of CAR-T were able to achieve a complete response following a second infusion of CAR-T.
